Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $99.8 million.

  • Monte Rosa Therapeutics' Free Cash Flow rose 566.40% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year increase of 330.98%. This contributed to the annual value of $38.0 million for FY2024, which is 160.48% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Free Cash Flow stood at $99.8 million for Q3 2025, which was up 374.00% from -$36.4 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Free Cash Flow ranged from a high of $128.7 million in Q4 2024 and a low of -$47.1 million during Q1 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Free Cash Flow averaged around -$777,455, with its median value being -$29.8 million (2024).
  • Over the last 5 years, Monte Rosa Therapeutics' Free Cash Flow had its largest YoY gain of 566.40% in 2025, and its largest YoY loss of 22.24% in 2025.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Free Cash Flow stood at $27.9 million in 2023, then surged by 360.69% to $128.7 million in 2024, then surged by 566.40% to $99.8 million in 2025.
  • Its last three reported values are $99.8 million in Q3 2025, -$36.4 million for Q2 2025, and -$47.1 million during Q1 2025.